Mirabella Financial Services LLP Purchases Shares of 3,700,000 MaxCyte, Inc. (NASDAQ:MXCT)

Mirabella Financial Services LLP acquired a new position in MaxCyte, Inc. (NASDAQ:MXCT) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 3,700,000 shares of the company’s stock, valued at approximately $15,392,000. MaxCyte accounts for about 1.4% of Mirabella Financial Services LLP’s investment portfolio, making the stock its 12th biggest holding.

A number of other institutional investors also recently bought and sold shares of the business. State Street Corp lifted its holdings in MaxCyte by 5.1% in the third quarter. State Street Corp now owns 2,269,135 shares of the company’s stock valued at $8,827,000 after acquiring an additional 111,066 shares during the period. Barclays PLC increased its position in shares of MaxCyte by 329.3% during the third quarter. Barclays PLC now owns 165,765 shares of the company’s stock worth $645,000 after purchasing an additional 127,156 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of MaxCyte by 2.0% during the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after buying an additional 47,960 shares in the last quarter. Franklin Resources Inc. acquired a new stake in MaxCyte in the 3rd quarter valued at about $260,000. Finally, SG Americas Securities LLC increased its holdings in shares of MaxCyte by 25.9% in the fourth quarter. SG Americas Securities LLC now owns 47,805 shares of the company’s stock valued at $199,000 after purchasing an additional 9,836 shares during the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Stock Up 2.4 %

Shares of NASDAQ:MXCT opened at $2.61 on Friday. The stock has a market cap of $277.48 million, a price-to-earnings ratio of -7.68 and a beta of 1.39. The firm’s 50 day moving average price is $3.16 and its 200 day moving average price is $3.73. MaxCyte, Inc. has a fifty-two week low of $2.21 and a fifty-two week high of $5.26.

Analyst Ratings Changes

MXCT has been the subject of a number of recent analyst reports. Stifel Nicolaus cut their price target on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the stock a “buy” rating in a research note on Wednesday, March 12th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.